Haisco Pharmaceutical Group (002653.SZ): Innovative drug Amber Acid Sipukawan tablets approved for market launch.
Hisen Co., Ltd. (002653.SZ) announced that on July 23, 2026, the company obtained approval from the National Medical Products Administration for the listing of the Class 1 innovative drug Sucrogluteopan tablets. This drug is indicated for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in adults who have not previously received complement inhibitor therapy.
Haisco Pharmaceutical Group (002653.SZ) announced that on July 23, 2026, the company received approval from the National Medical Products Administration for the marketing of their Class 1 innovative drug, Sipokelan tablets containing succinic acid. This drug is indicated for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in adult patients who have not previously received complement inhibitors therapy.
Related Articles
TSAKER NE(01986) announces a half-year profit of no less than 90 million yuan for shareholders, with a year-on-year growth rate of no less than 867.7%.
KEYMED BIO-B (02162): CM512 has been included in the list of breakthrough therapies by the National Medical Products Administration Drug Evaluation Center.
HK Stock Market Move | LYGEND RESOURCE (02245) rose over 7% again, and the A-share main board IPO has been successfully passed. The net profit for the first half of the year is expected to increase by 50% to 70%.
TSAKER NE(01986) announces a half-year profit of no less than 90 million yuan for shareholders, with a year-on-year growth rate of no less than 867.7%.
KEYMED BIO-B (02162): CM512 has been included in the list of breakthrough therapies by the National Medical Products Administration Drug Evaluation Center.
HK Stock Market Move | LYGEND RESOURCE (02245) rose over 7% again, and the A-share main board IPO has been successfully passed. The net profit for the first half of the year is expected to increase by 50% to 70%.
RECOMMEND
